Prevention and treatment of cardiac hypertrophy with wogonin (P - 933)
DKFZ Deutsches Krebsforschungszentrum
In recent years, many efforts have been made to find compounds for the treatment of cardiac diseases. Traditional approaches to the suppression of cardiac hypertrophy have focused on outsidein signaling, e.g. to block neurohormones or calcium triggers. However, these treatments vary in effectiveness. Wogonin is the active component of extracts of the herbal remedy Scutellaria baicalensis, which is used intraditional Chinese medicine for the treatment of diseases such ashyperlipidemia, atherosclerosis, hypertension, dysentery, common cold and atopic dermatitis. Wogonin shows low toxicity in different animal models.
Cardiac hypertrophy is characterized by a globalincrease in transcription and protein per cell. Cyclin-dependent kinase 9 (CDK9) is the maindriver for transcription and is necessary for hypertrophy in cardiomyocytes (Sano et al., 2002, 2004; Kulkarni et al., 2004). DKFZ scientists have shown that wogoninis a potent inhibitor of CDK9 with no, or very low, toxicity to normal tissues (Polier et al., 2011; Talbiet al., 2014). Wogonin can be used for preventing cardiac hypertrophy.
- Cardiac hypertrophy is a serious medical problem for many people in various countries
- Wogonin reduces at least one or more symptoms of cardiac hypertrophy
- Wogonin can be used to prevent cardiac hypertrophy and its associated symptoms
In-vitro verified technology. Preliminary clinical experiments are ongoing.
Applications and Commercial Opportunity
Wogonin can be isolated from the roots of Scutellaria baicalensisor prepared by chemical synthesis. Wogonin also shows anticancer activities in various tumor cells. DKFZ is seeking a commercial partner interested in this promising new application.